Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.

ABSTRACT:

Background

Pertuzumab increases the rate of pathological complete response in the preoperative context and increases overall survival among patients with metastatic disease when it is added to trastuzumab and chemotherapy for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer. In this trial, we investigated whether pertuzumab, when added to adjuvant trastuzumab and chemotherapy, improves outcomes among patients with HER2-positive early breast cancer.

Methods

We randomly assigned patients with node-positive or high-risk node-negative HER2-positive, operable breast cancer to receive either pertuzumab or placebo added to standard adjuvant chemotherapy plus 1 year of treatment with trastuzumab. We assumed a 3-year invasive-disease-free surviv

SUBMITTER: von Minckwitz G 

PROVIDER: S-EPMC5538020 | biostudies-literature | 2017 Jul

REPOSITORIES: biostudies-literature